Leerink Partners analyst Puneet Souda maintained a Buy rating on Guardant Health (NASDAQ:GH) on Friday, setting a price target of $190, which is approximately 40.34% above the present share price of $135.39.
Souda expects Guardant Health to post earnings per share (EPS) of -$0.94 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Guardant Health, with an average price target of $179.17.
The analysts price targets range from a high of $195 to a low of $160.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $78.32 million and a net profit of -$91.17 million. The company's market cap is $13.69 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.2% and a 60.63% success rate.
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood (NYSE:RWT) City, CA.